Skip to main content
. Author manuscript; available in PMC: 2021 Aug 28.
Published in final edited form as: ACS Appl Nano Mater. 2020 Aug 7;3(8):8037–8051. doi: 10.1021/acsanm.0c01506

Figure 2. CPMV in situ vaccination administered by active microneedle (MN) patches, passive MN patches or intratumoral injection in B16F10 dermal melanoma model.

Figure 2.

(a) Microneedle patches were cut into smaller pieces (total of 4 or 9 pieces equaling full 100 μg CPMV dose) to cover tumor area. (b) Tumor volumes of mice receiving 30 μL PBS injection (PBS, blue), 100 μg in 30 μL CPMV injection (CPMV, red), CPMV passive microneedle (MN, green), and CPMV active MN (purple) after treatment administration (on day 7 after intradermal B16F10 melanoma cell inoculation). Data are mean ± standard deviation (SD) (n=5 for all treatment groups except for active MN group, n=6). Tumor growth was compared on different time points by one-way ANOVA with Tukey’s test: *P<0.05, **P<0.01, ***P<0.001. (c) Clinical appearance of representative PBS-, CPMV injection-, and active MN-treated tumors 3 and 7 days after treatment. (d) At day 3 post treatment, CPMV injection-treated tumors vary between exophytic and involuted appearance. Active MN treated-tumors more consistently have an involuted appearance.